AOD-9604 + Tesamorelin: Ultimate Fat Loss Stack

Category: Stacks Type: Protocol Read Time: 17 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/aod-9604-tesamorelin-stack

Disclaimer: This content is for educational purposes only and is not medical advice. Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy but is being discussed here in an off-label body-recomposition context. AOD-9604 is a research compound and is NOT FDA-approved for human use. GLP-1 receptor agonists (semaglutide, tirzepatide) produce substantially larger weight-loss outcomes in clinical trials than the stack described in this guide. Always consult a qualified healthcare provider before starting any peptide protocol.

Overview

The AOD-9604 + Tesamorelin stack pairs two fat-targeting peptides with complementary mechanisms. AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (residues 176-191) that retains the lipolytic activity of GH without the growth or insulin-resistance effects. Tesamorelin is a stabilized GHRH analog that increases endogenous GH and IGF-1 with a documented preference for visceral adipose tissue reduction.

Together they create a body-recomposition strategy that targets fat from two angles: AOD provides a direct lipolytic signal at the adipocyte, while Tesamorelin shifts whole-body metabolism toward fat oxidation and preserves lean mass via IGF-1.

A few important framings:

• This stack is not a substitute for a caloric deficit. Fat loss still requires energy out > energy in.
• This stack is not a substitute for GLP-1 receptor agonists. Semaglutide and tirzepatide produce 15-22% body weight reduction in trials; this stack is more aligned with body composition refinement at 3-8% range.
• This is a body-recomposition protocol, not a weight-loss drug.

Why Combine Them — Mechanism Overlap & Synergy

The two peptides are mechanistically distinct, which is exactly why they stack well rather than redundantly.

The synergy: AOD acts locally to mobilize fatty acids from the adipocyte, while Tesamorelin upregulates the metabolic machinery (GH/IGF-1 axis) that oxidizes them. AOD without a metabolic ramp tends to mobilize fat that gets re-esterified; Tesamorelin without a direct lipolytic stimulus mobilizes fat more slowly. The combination addresses both supply and demand sides of fat metabolism.

Stack Composition

Standard dosing for the combined stack:

Key timing rationale:

• Tesamorelin at night mimics endogenous GH pulse timing and avoids blunting from food intake
• AOD in the AM fasted aligns the lipolytic signal with low-insulin state for maximum fat oxidation
• 5-7 day frequency balances receptor sensitivity with consistent signal

Most users start at the lower end of both ranges and titrate upward based on tolerance and bloodwork.

Why GLP-1 Comparison Matters

This is the section most stack guides skip — and it's the most important.

Honest comparison:

The AOD/Tesamorelin stack is not competing with GLP-1s on scale-weight outcomes. It is a body composition and visceral fat tool. People who need to lose 40+ pounds will get better results from a GLP-1. People who are already lean-ish, want to refine composition, target visceral fat, and preserve muscle — this stack makes more sense.

If you are obese and looking for the most effective pharmacologic fat-loss option available, a GLP-1 from a licensed provider is the honest answer.

Sample 12-Week Stack Protocol

Total active stack duration: 12-14 weeks, followed by a structured washout of at least 8 weeks before considering re-stacking.

Diet & Training Integration

Peptides amplify what's already happening. Without inputs, they have nothing to amplify.

Caloric deficit:

• Modest: 250-500 kcal below maintenance
• The peptides do not require aggressive deficits to work; in fact, very low calorie diets can blunt the GH/IGF-1 response Tesamorelin depends on
• Refeed days (maintenance calories) once weekly can preserve thyroid output

Protein intake:

• Target 1.0 g per pound of lean body mass (roughly 0.8-1.0 g/lb total bodyweight if not obese)
• Critical for muscle preservation during fat loss
• Distribute across 3-5 meals

Resistance training:

• 3-5 sessions per week
• Compound movements prioritized
• This is non-negotiable for body recomposition — the stack will not preserve muscle if you don't load it

Cardio (optional but synergistic):

• Zone 2 cardio (60-70% max HR) in the AM after AOD injection
• 30-45 minutes, 3-4x per week
• Aligns oxidation capacity with the lipolytic signal
• Avoid high-intensity cardio fasted; it can blunt recovery and elevate cortisol

Expected Outcomes

Timeline of typical responses across a 12-week stack:

Weeks 1-2:

• Slight injection site warmth or redness with Tesamorelin
• Mild morning energy increase from AOD
• Sleep quality often improves (Tesamorelin)
• No measurable composition change yet

Weeks 3-6:

• Waist circumference begins decreasing (Tesamorelin's visceral signature)
• Morning resting heart rate may rise 3-5 bpm (GH-related)
• Skin texture improvements
• Subcutaneous fat changes lag visceral changes

Weeks 7-12:

• Visceral fat reduction becomes visible — flatter midsection
• Subcutaneous reduction more apparent with continued deficit
• Lean mass typically preserved or modestly increased with resistance training
• IGF-1 climbs to upper-mid range for age (target zone)

Realistic numbers:

• 3-8% body fat reduction depending on starting point
• Visceral adipose tissue: 15-25% reduction (Tesamorelin's strength)
• Lean mass: preserved or +1-2 lbs
• Scale weight: often less dramatic than visual change suggests

Bloodwork to Monitor

Baseline and 12-week comparison panel:

If IGF-1 climbs above the age-adjusted upper limit, reduce Tesamorelin dose. Do not chase higher numbers — supraphysiological IGF-1 carries oncologic and cardiac concerns.

Side Effects & Safety

Tesamorelin:

• Injection site reactions (most common — redness, itching, mild swelling)
• Fluid retention (peripheral edema, especially first 2-4 weeks)
• Arthralgia (joint achiness)
• Hyperglycemia risk — most relevant for those with insulin resistance
• Carpal tunnel-like symptoms (rare, dose-dependent)
• Modest increase in resting heart rate

AOD-9604:

• Well-tolerated in available research
• Occasional injection site reaction
• No documented impact on glucose or IGF-1
• Headache reported infrequently

Cumulative stack considerations:

• Monitor glucose closely if there's any baseline insulin resistance
• Check blood pressure weekly during titration
• Stop and consult a provider if persistent edema, vision changes, or severe joint pain develops
• Not appropriate during active malignancy, pregnancy, or for children/adolescents

Optional Additions to the Stack

For users who want to build on the base stack — with full understanding of cost and complexity tradeoffs:

Adding everything is not better. Most users get >80% of the benefit from the base AOD + Tesamorelin stack with diet and training dialed in.

Cycling

Tesamorelin and AOD-9604 are typically run in 12-16 week blocks, not continuously.

Standard cycling pattern:

• 12-16 weeks on
• 8-12 weeks off
• Repeat 1-2 times per year

Why cycle:

• Receptor sensitivity preservation (especially for the GHRH pathway)
• Allows IGF-1 to return to baseline between cycles
• Reduces cumulative cost
• Easier to assess what the stack actually contributed vs. lifestyle

Strategic timing:

• Many users plan cycles around photo shoots, weddings, beach season, or competition prep
• Backward-plan from the goal date: peak conditioning should land around week 10-12 of the cycle
• The taper phase preserves results while the GH axis normalizes

Stack vs Monotherapy

When does the stack make sense vs. running just one peptide?

Run Tesamorelin alone if:

• Visceral fat is the primary concern
• Budget is constrained
• You want the most evidence-backed option (it's the only FDA-approved one)

Run AOD-9604 alone if:

• You want a gentler lipolytic signal without IGF-1 elevation
• You have any concern about glucose or GH effects
• Cost is a major factor

Run the full stack if:

• You're chasing meaningful body composition change (not just scale weight)
• Visceral and subcutaneous fat are both targets
• You can commit to the training and diet infrastructure
• Budget allows ($400-800/month at typical compounding pharmacy prices)

Honest cost-benefit: The stack is expensive, requires nightly + morning injections, demands disciplined diet and training, and produces results that — for many users — are achievable with diet and training alone over a longer timeline. The peptides accelerate and refine. They don't replace.

If you wouldn't do the work without them, they probably aren't the right tool yet.

Frequently Asked Questions

Q: Is this stack better than semaglutide for weight loss? A: No. For raw weight loss magnitude, GLP-1s outperform this stack significantly. The AOD/Tesamorelin stack is better characterized as a body composition and visceral fat tool. Different goals, different tools.

Q: Can I stack this with a GLP-1? A: Some users do. The combination can produce dramatic results but also stacks side effect profiles (GI from GLP-1, glucose/edema from Tesamorelin). Only with provider supervision and aggressive bloodwork monitoring.

Q: How much fat loss is realistic over a 12-week cycle? A: For someone with proper diet and training: typically 3-8% body fat reduction, 15-25% visceral adipose reduction, and preserved or slightly increased lean mass. Scale weight changes are often modest because lean mass is preserved.

Q: Should I inject Tesamorelin morning or night? A: Night is preferred. It mimics endogenous GH pulse timing and avoids interference from food. AOD goes in the morning. Don't combine them in the same injection.

Q: Will insurance cover Tesamorelin? A: Only for FDA-approved HIV-associated lipodystrophy. Off-label use for body composition is virtually always out-of-pocket. Compounding pharmacies typically offer it at substantially lower cost than the branded product.

Q: How long until I see results? A: Subjective changes in energy and sleep: 1-2 weeks. Waist circumference changes: 4-6 weeks. Visible composition shift: 8-12 weeks. Most of the visual payoff arrives in the back half of the cycle.

Q: Can women use this stack? A: Yes, often at lower doses (Tesamorelin 1.0-1.5 mg, AOD 200-300 mcg). Women may be more sensitive to fluid retention. Not for use during pregnancy, breastfeeding, or for those trying to conceive.

Q: What happens when I stop the stack? A: Fat loss results are maintained as long as caloric balance and training are maintained. Tesamorelin's effect on the GH axis returns to baseline within 2-4 weeks. There is no withdrawal or rebound mechanism, but bad habits will reverse results.

Related Content

• Tesamorelin Protocol
• AOD-9604 Protocol
• Fragment 176-191 Protocol
• GH Peptide Stacking Guide
• 5-amino-1MQ Protocol
• Bloodwork Checklist

Disclaimer: This content is for educational purposes only and is not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; off-label use is at your healthcare provider's discretion. AOD-9604 is a research compound not FDA-approved for human use. GLP-1 receptor agonists produce larger weight-loss outcomes than the stack described here. Consult a qualified healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/aod-9604-tesamorelin-stack